Since NOX4 acts upstream of the adverse effects of TGF-β1, targeting NOX4 can more effectively prevent TGF-β1-driven harmful cascade reactions, making NOX4 inhibitors a potential method for treating ALI. This evidence concerns the gene TGFB1 and acute respiratory distress syndrome.